Dicerna (RNAi therapies) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Dicerna (RNAi therapies) General Information

Description

Two discovery-stage RNAi (ribonucleic acid interference) programs and two undisclosed assets. The RNAi therapies block the production of complement pathway factors stopping the uncontrolled complement activation that underpins many diseases such as chronic liver, cardiovascular, and viral infectious diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 87 Cambridgepark Drive
  • Cambridge, MA 02140
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Delivery
Biotechnology
Acquirer
Alexion
Vertical(s)
Life Sciences
Corporate Office
  • 87 Cambridgepark Drive
  • Cambridge, MA 02140
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dicerna (RNAi therapies) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dicerna (RNAi therapies)‘s full profile, request access.

Request a free trial

Dicerna (RNAi therapies) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dicerna (RNAi therapies)‘s full profile, request access.

Request a free trial

Dicerna (RNAi therapies) FAQs

  • Where is Dicerna (RNAi therapies) headquartered?

    Dicerna (RNAi therapies) is headquartered in Cambridge, MA.

  • What industry is Dicerna (RNAi therapies) in?

    Dicerna (RNAi therapies)’s primary industry is Buildings and Property.

  • Is Dicerna (RNAi therapies) a private or public company?

    Dicerna (RNAi therapies) is a Private company.

  • What is Dicerna (RNAi therapies)’s current revenue?

    The current revenue for Dicerna (RNAi therapies) is .

  • Who are Dicerna (RNAi therapies)’s investors?

    Dicerna Pharmaceuticals has invested in Dicerna (RNAi therapies).

  • When was Dicerna (RNAi therapies) acquired?

    Dicerna (RNAi therapies) was acquired on 24-Oct-2018.

  • Who acquired Dicerna (RNAi therapies)?

    Dicerna (RNAi therapies) was acquired by Alexion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »